NHS National Framework for Transition products commencing 1 October 2024
Estimated value
£41.3m
Awarded value
£16.2m
Suppliers
1
Lots
1
Published
17 Oct 2024
Description
Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Scope
- Reference
- CF-2641700D0O000000rwimUAA
- Total value
- £41,320,000 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 30 Sept 2024 to 30 May 2026
- CPV classifications
- 33600000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 31 Jul 2024, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£16.2m
Award date
29 Sept 2024
Contract start
30 Sept 2024
Contract end
30 May 2026